Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408780 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects
A Phase 1 study, sponsored by Cerecin.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT05408780: Completed Phase 1 study, sponsored by Cerecin.
NCT05408780 is a Phase 1 study that has completed, run by Cerecin. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05408780, a Phase 1 study, has completed, sponsored by Cerecin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.
Interventions
- DRUG AC-OLE-01-VA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2022-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05408780
The ClinicalTrials.gov registry entry for NCT05408780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerecin, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AC-OLE-01-VA is the first listed.
NCT05408780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05408780 about?
NCT05408780 is a clinical study titled "A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects". The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.
What is the current status of trial NCT05408780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-07-14. Estimated completion is 2022-10-24.
What interventions are being tested in trial NCT05408780?
The interventions under investigation include: AC-OLE-01-VA (DRUG).
Who is sponsoring clinical trial NCT05408780?
This trial is sponsored by Cerecin, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.